新开利安生物科技（海南）有限公司借自贸港“东风”链接全球

Core Viewpoint - New Kailian Biotechnology (Hainan) Co., Ltd. has successfully broken the foreign monopoly on the production of reduced coenzyme Q10, establishing itself as the only domestic company with complete independent intellectual property rights and certification in this field, enabling its products to be exported to 16 countries worldwide [1][2]. Group 1: Company Overview - New Kailian is located in the Haikou National High-tech Zone and specializes in the mass production of reduced coenzyme Q10, a critical substance for cellular energy [1]. - The company has developed a patented technology for the preparation of reduced coenzyme Q10, which significantly enhances bioavailability and absorption rates by over 60% compared to traditional oxidized products [1]. Group 2: Market Strategy - The choice of Hainan as a base is a strategic decision aimed at targeting international markets, leveraging the unique policy advantages of the Hainan Free Trade Port [3]. - The company has established a complete technological closed loop from gene engineering strains to patented crystalline forms and large-scale production, facilitating entry into high-end markets in Europe and North America [2][3]. Group 3: Operational Efficiency - New Kailian has achieved rapid operational success, with plans to reach an annual production capacity of 160 tons, exceeding the current global demand of 100 tons per year [4]. - The company benefits from a direct international shipping route to New Zealand, reducing transportation costs by at least $10 per kilogram and improving delivery efficiency [4]. Group 4: Future Growth Plans - The company anticipates a compound annual growth rate of over 30% in the next three years, supported by the zero-tariff policy for imported raw materials [4]. - New Kailian is actively pursuing collaborations with international brands to enhance its market presence and brand value, aiming to become a leading player in the reduced coenzyme Q10 sector [5].